Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Description
We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
No
In Person
Yes
Types of Training
Training Docs
No
Webinars
No
Live Training (Online)
No
In Person
No
Vendor Details
Company Name
Atomwise
Founded
2012
Country
United States
Website
www.atomwise.com
Vendor Details
Company Name
BioSymetrics
Country
United States
Website
www.biosymetrics.com/platform